Drug pricing, reimbursement policy, coverage decisions
Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo …
Brazil’s Health Ministry has formally asked Conitec to evaluate semaglutide and liraglutide for public-system coverage, opening a process that could reshape the country’s obesity-drug market.
The first new-class painkiller in decades has near-universal US coverage and negligible sales — and no clear path to Latin American patients.
Colombia’s Ministry of Health declared public interest grounds to pursue mandatory licensing of Gilead’s sofosbuvir-based hepatitis C patents, transferring the process to the competition authority for a final determination.
Uruguay’s Ministry of Public Health and mutual insurers have agreed to incorporate 12 high-cost medicines into the national formulary, reducing per-unit acquisition costs from up to 100,000 pesos to approximately …
Clinics across four Patagonian provinces suspended all PAMI patient care for 24 hours, citing a 143% tariff adjustment against 341% cumulative inflation — a gap that may signal broader provider …
PASSUS IPS, a Colombian healthcare provider, has warned it may suspend services due to unpaid debts from EPS insurers, exposing a structural financing gap in Colombia’s health system.
You must be logged in to post a comment.